{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:33:14Z","timestamp":1784586794423,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a lack of knowledge on effective treatment methods for comorbid benzodiazepine dependence in populations undergoing opioid agonist treatment (OAT). Tapering and discontinuation of benzodiazepines has long been considered the standard treatment, even though there is limited evidence for this practice. There is also limited research on benzodiazepine agonist treatment; however, peer and clinical experiences indicate that such approaches may be beneficial for a subgroup of the patients with long-lasting benzodiazepine dependence not responding to other treatment approaches. A randomized controlled trial will be conducted to compare the efficacy and safety of stabilizing agonist treatment using prescribed benzodiazepines with standard treatment in reducing illicit benzodiazepine use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The target sample is 108 participants at outpatient OAT clinics in six Norwegian cities\/counties (Bergen\/Vestland, T\u00f8nsberg\/Vestfold, Skien\/Telemark, Fredrikstad\/\u00d8stfold, Troms\u00f8\/Troms, and Lillestr\u00f8m\/Akershus). The main inclusion criteria are benzodiazepine dependence of\u2009\u2265\u20095\u00a0years, using\u2009\u2265\u20095\u00a0days a week during the last month, and previous attempts at tapering. Participants will be randomly assigned to receive either a 26-week benzodiazepine stabilizing treatment (15\u201330\u00a0mg diazepam or 50\u2013100\u00a0mg oxazepam daily), or a 20-week tapering using the same medications and equivalent initial dosages. All participants will be given access to consultations from OAT therapists with psychosocial follow-up in accordance with current clinical practice.<\/jats:p>\n                    <jats:p>The primary outcome is the use of illicit benzodiazepines assessed by observed urinary tests at week 24. Secondary outcomes include mental health symptoms, quality of life, cognitive performance, violence risk, other substance use, treatment retention, and life satisfaction. Additionally, the study will assess treatment-related adverse events as well as the cost-effectiveness of the intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This is the first randomized controlled trial of benzodiazepine agonist treatment for benzodiazepine dependence. The research project will assess efficacy and safety of stabilizing treatment with prescribed benzodiazepines compared to benzodiazepine tapering and discontinuation regarding use of illicit benzodiazepines and accordingly well-being of patients with concurrent benzodiazepine and opioid dependence undergoing OAT. If the intervention is found to be efficacious and safe, it will be considered one of the options to standard treatment for this patient group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>EU trial number: EudraCT: 2021\u2013004981-37. Registered on December 13, 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-024-08692-8","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T01:10:31Z","timestamp":1735780231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Benzodiazepine agonist treatment for patients with benzodiazepine dependence undergoing opioid agonist treatment: a study protocol for the randomized controlled trial BMX-BAR"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1242-1972","authenticated-orcid":false,"given":"Fatemeh","family":"Chalabianloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Thore","family":"Fadnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Assmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Mordal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin K.","family":"Solli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil S.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina D.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Zavenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beathe H.","family":"R\u00f8nning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas W.","family":"Blomkvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ryssdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasifa S. J.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Marciuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne G.","family":"\u00d8rmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ohldieck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else-Marie","family":"L\u00f8berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell Arne","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the BMX-BAR and NORCATS study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svanhild","family":"Mellingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Olsvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette H.","family":"Nordbotn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate H.","family":"Trettenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine U.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Sannerud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Sundal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Pierron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Moe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Alibhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline N.","family":"Helg\u00f8y","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Vedaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Holtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi F.","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt K.","family":"Haugen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine T.H.","family":"Karlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kaspersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linn C.W.","family":"Digranes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"issue":"1","key":"8692_CR1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12913-020-05195-5","volume":"20","author":"JH Vold","year":"2020","unstructured":"Vold JH, Skurtveit S, Aas C, Chalabianloo F, Kloster PS, Johansson KA, Fadnes LT. Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017. BMC Health Serv Res. 2020;20(1):352.","journal-title":"BMC Health Serv Res"},{"key":"8692_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","volume":"200","author":"VR Votaw","year":"2019","unstructured":"Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: A systematic review. Drug Alcohol Depend. 2019;200:95\u2013114.","journal-title":"Drug Alcohol Depend"},{"key":"8692_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.01.013","volume":"174","author":"T Abrahamsson","year":"2017","unstructured":"Abrahamsson T, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58\u201364.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"8692_CR4","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1111\/j.1360-0443.2010.02933.x","volume":"105","author":"M Liebrenz","year":"2010","unstructured":"Liebrenz M, Boesch L, Stohler R, Caflisch C. Agonist substitution\u2014a treatment alternative for high-dose benzodiazepine-dependent patients? Addiction. 2010;105(11):1870\u20134.","journal-title":"Addiction"},{"key":"8692_CR5","unstructured":"Waal H, Clausen T.\u00a0Kan substitusjonsbehandling v\u00e6re et alternativ ved avhengighet av amfetamin\/metamfetamin, kokain, cannabis og benzodiazepiner?\u00a0Senter for rus-og avhengighetsorskning (SERAF). Oslo, 2020.https:\/\/www.med.uio.no\/klinmed\/forskning\/sentre\/seraf\/publikasjoner\/rapporter\/2020\/seraf-rapport-2-2020-substitusjonbehandling-andre-rusmidler.pdf."},{"issue":"11","key":"8692_CR6","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1111\/j.1360-0443.2010.03177.x","volume":"105","author":"M Liebrenz","year":"2010","unstructured":"Liebrenz M, Boesch L, Stohler R, Caflisch C. Benzodiazepine dependence: when abstinence is not an option. Addiction. 2010;105(11):1877\u20138.","journal-title":"Addiction"},{"issue":"10","key":"8692_CR7","first-page":"1027","volume":"140","author":"JA Andersson","year":"2020","unstructured":"Andersson JA, Brekke M, Vallersnes OM. Akutt forgiftning ved rusrelatert bruk av benzodiazepiner. Tidsskri Nor Legeforen. 2020;140(10):1027\u201330.","journal-title":"Tidsskri Nor Legeforen"},{"issue":"11","key":"8692_CR8","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/j.1360-0443.1994.tb03743.x","volume":"89","author":"H P\u00e9tursson","year":"1994","unstructured":"P\u00e9tursson H. The benzodiazepine withdrawal syndrome. Addiction. 1994;89(11):1455\u20139.","journal-title":"Addiction"},{"key":"8692_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/YIC.0b013e328105e0f2","volume":"22","author":"S Petitjean","year":"2007","unstructured":"Petitjean S, Ladewig D, Meier CR, Amrein R, Wiesbeck GA. Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol. 2007;22:292\u20138.","journal-title":"Int Clin Psychopharmacol"},{"key":"8692_CR10","unstructured":"Norwegian Health Directorate. National guidelines for the treatment of opioid dependence. Updated May 2024. https:\/\/www.helsedirektoratet.no\/retningslinjer\/behandling-ved-opioidavhengighet."},{"issue":"1","key":"8692_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13011-020-00309-y","volume":"15","author":"CF Aas","year":"2020","unstructured":"Aas CF, Vold JH, Skurtveitt S, Lim AG, Ruths S, Islam K, Askildsen JE, L\u00f8berg E-M, Fadnes LT, Johansson KA, INTRO-HCV Study Group. Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway. Subst Abuse Treat Prev Policy. 2020;15(1):68.","journal-title":"Subst Abuse Treat Prev Policy."},{"issue":"1","key":"8692_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1521-0391.2009.00007.x","volume":"19","author":"N Lintzeris","year":"2010","unstructured":"Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: interactions and clinical management. Am J Addict. 2010;19(1):59\u201372.","journal-title":"Am J Addict"},{"issue":"23","key":"8692_CR13","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.2174\/1381612821666150619092039","volume":"21","author":"P Sabioni","year":"2015","unstructured":"Sabioni P, Bertram J, Le Foll B. Off-Label Use of Medications for Treatment of Benzodiazepine Use Disorder. Curr Pharm Des. 2015;21(23):3306\u201310.","journal-title":"Curr Pharm Des"},{"key":"8692_CR14","unstructured":"Skeie I. Knowledge on substitution treatment with benzodiazepines in people undergoing opioid agonist treatment with co-morbid benzodiazepine dependence; 2020. [Unpublished data]. In: Norwegian Health Directorate. National guidelines for the treatment of opioid dependence. Updated May 2022. https:\/\/www.helsedirektoratet.no\/retningslinjer\/behandling-ved-opioidavhengighet\/behandling-ved-opioidavhengighet\/ved-avhengighet-til-benzodiazepiner-hos-pasienter-i-lar-anbefales-psykososial-behandling-og-nedtrapping-av-benzodiazepiner."},{"issue":"4","key":"8692_CR15","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1046\/j.1440-1614.2003.01211.x","volume":"37","author":"T Weizman","year":"2003","unstructured":"Weizman T, Gelkopf M, Melamed Y, Adelson M, Bleich A. Treatment of Benzodiazepine Dependence in Methadone Maintenenace Treatment Patients: A Comparison of Two Therapeutic Modalities and the Role of Psychiatric Comorbidity. Aust N Z J Psychiatry. 2003;37(4):458\u201363.","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"8692_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","volume":"18","author":"MJ Barker","year":"2004","unstructured":"Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18(1):37\u201348.","journal-title":"CNS Drugs"},{"issue":"5","key":"8692_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/add.14886","volume":"115","author":"TW Park","year":"2020","unstructured":"Park TW, Larochelle MR, Saitz R, Wang N, Bernson D, Walley AY. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine. Addiction. 2020;115(5):924\u201332.","journal-title":"Addiction"},{"issue":"11","key":"8692_CR18","doi-asserted-by":"publisher","first-page":"e1002965","DOI":"10.1371\/journal.pmed.1002965","volume":"16","author":"J Macleod","year":"2019","unstructured":"Macleod J, Steer C, Tilling K, Cornish R, Marsden J, Millar T, Hickman M. Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records. PLoS Med. 2019;16(11):e1002965.","journal-title":"PLoS Med"},{"key":"8692_CR19","unstructured":"Edvardsen HME, Clausen T. Opioids related deaths during 2000\u20132017 in Oslo. Oslo University Hospital; 2020. https:\/\/oslo-universitetssykehus.no\/fag-og-forskning\/nasjonale-og-regionale-tjenester\/rettsmedisinske-fag\/alkohol-og-r."},{"issue":"2","key":"8692_CR20","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2468-2667(24)00001-X","volume":"9","author":"A Holland","year":"2024","unstructured":"Holland A, Copeland CS, Shorter GW, Connolly DJ, Wiseman A, Mooney J, Kevin Fenton K, Harris M. Nitazenes-heralding a second wave for the UK drug-related death crisis? Lancet Public Health. 2024;9(2):e71\u20132. https:\/\/doi.org\/10.1016\/S2468-2667(24)00001-X. (Epub 2024 Jan 12).","journal-title":"Lancet Public Health"},{"issue":"12","key":"8692_CR21","doi-asserted-by":"publisher","first-page":"e2348557","DOI":"10.1001\/jamanetworkopen.2023.48557","volume":"6","author":"DT Maust","year":"2023","unstructured":"Maust DT, Petzold K, Strominger J, Kim HM, Bohnert ASB. Discontinuation and Mortality Among Patients With Long-Term Benzodiazepine Therapy. JAMA Netw Open. 2023;6(12): e2348557. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.48557.","journal-title":"JAMA Netw Open"},{"key":"8692_CR22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/070674370605100706","volume":"51","author":"RC Voshaar","year":"2006","unstructured":"Voshaar RC, Gorgels WJ, Mol AJ, van Balkom AJ, Mulder J, van de Lisdonk EH, et al. Predictors of long-term benzodiazepine abstinence in participants of a randomized controlled benzodiazepine withdrawal program. Can J Psychiatry. 2006;51:445\u201352.","journal-title":"Can J Psychiatry"},{"key":"8692_CR23","unstructured":"SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials). 2013.\nhttp:\/\/www.spirit-statement.org\/."},{"issue":"1","key":"8692_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bs.3830190102","volume":"19","author":"LR Derogatis","year":"1974","unstructured":"Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci. 1974;19(1):1\u201315.","journal-title":"Behav Sci"},{"issue":"10","key":"8692_CR25","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version\u00a0of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"key":"8692_CR26","unstructured":"Reaction time test (online version). How old are your reactions? https:\/\/www.justpark.com\/creative\/reaction-time-test\/. Accessed 15 Aug 2022."},{"key":"8692_CR27","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1177\/088626000015012003","volume":"15","author":"R Almvik","year":"2000","unstructured":"Almvik R, Woods P, Rasmussen K. The Br\u00f8set Violence Checklist: Sensitivity, specificity and interrater reliability. J Interpers Violence. 2000;15:1284\u201396.","journal-title":"J Interpers Violence"},{"key":"8692_CR28","volume-title":"Fundamentals of Biostatistics","author":"B Rosner","year":"2011","unstructured":"Rosner B. Fundamentals of Biostatistics. 7th ed. Boston, MA: Brooks\/Cole; 2011.","edition":"7"},{"issue":"9263","key":"8692_CR29","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","volume":"357","author":"D Moher","year":"2001","unstructured":"Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357(9263):1191\u20134.","journal-title":"Lancet"},{"issue":"9460","key":"8692_CR30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S0140-6736(05)17965-3","volume":"365","author":"DAMOCLES Study Group","year":"2005","unstructured":"DAMOCLES Study Group. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005;365(9460):711\u201322.","journal-title":"Lancet"},{"issue":"2","key":"8692_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","volume":"18","author":"SD Ramsey","year":"2015","unstructured":"Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, Briggs A, Sullivan SD. Cost-Effectiveness Analysis Alongside Clinical Trials II\u2014An ISPOR Good Research Practices Task Force Report. Value Health. 2015;18(2):161\u201372.","journal-title":"Value Health"},{"key":"8692_CR32","unstructured":"Oksazepam (Sobril). Summary of Product Characteristics (SPC). Norwegian Medical Products Agency. Updated August 2021. https:\/\/www.legemiddelsok.no\/sider\/default.aspx?searchquery=Valium&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=0."},{"key":"8692_CR33","unstructured":"Diazepam (Valium). Summary of Product Characteristics (SPC). Norwegian Medical Products Agency. Updated January 2021. https:\/\/www.legemiddelsok.no\/sider\/default.aspx?searchquery=Valium&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=0."},{"key":"8692_CR34","unstructured":"ANRS scale to grade the severity of adverse events in adults. 2008. http:\/\/www.anrs.fr\/content\/download\/2242\/12805\/file\/ANRS-GradeEI-V1-En-2008.pdf."},{"key":"8692_CR35","unstructured":"International committee of medical journal editors. Updated January 2024. http:\/\/www.icmje.org\/recommendations\/."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08692-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08692-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08692-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T14:01:53Z","timestamp":1735826513000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08692-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8692"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08692-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4868655\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"10 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is approved by regional ethical committee (Reference number 345516- REK Vest) and drug administration authorities in Norway and registered at www.clinicaltrials.gov. Written informed consent will be obtained from all the participants before commencing to the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"This manuscript does not contain individual personal data and the participants have given written informed consent for the publication of the study findings.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no cometing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"2"}}